drugset / Trial / NCT06832618

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618

Phase 3 Active not recruiting 159 enrolled Incyte Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.

Timeline

Start
2025-06-17
Primary completion
2026-07-13
Completion
2028-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 1.5 % Topical

Indications